Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...

Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which ...

US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...

Sciences announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81%, ...

Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

We are very encouraged by the launch of Livdelzi for primary biliary cholangitis or PBC, which was granted accelerated approval by the FDA in August. Livdelzi is a highly differentiated option for ...

Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.

Foster City, Calif.-based Gilead (GILD) had net income of $1.25 billion, or $1.00 a share, for the quarter, down from $2.18 billion, or $1.73 a share, in the year-earlier period. Adjusted for one-time ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...